Acrotech Biopharma, a subsidiary of Aurobindo Pharma, has launched Adquey in the U.S. for the treatment of mild-to-moderate atopic dermatitis and established a dedicated dermatology business unit.
The launch marks Acrotech’s entry into the US dermatology market and expands the company’s commercial presence into a new strategic therapeutic area. To support the launch of Adquey and its long-term ambitions in dermatology, Acrotech has established a dedicated dermatology business unit with specialiSed commercial capabilities across marketing, sales and field-based engagement.
The product will compete in a market estimated to be around $1.3 billion for the twelve months ending July 2026, according to IQVIA MAT.
“The launch of Adquey is an important milestone for Acrotech and marks our entry into the US dermatology market with a differentiated treatment option for patients living with atopic dermatitis,” Ashish Anvekar, President, Acrotech Biopharma said in a release.”
“We are building more than a commercial organization around a single product. We are establishing a dedicated dermatology platform designed to support Adquey today while creating the capabilities to pursue additional opportunities that can address important unmet needs in dermatologic care,’’ he added.
Published on October 1, 2026
